Powered by

Orexigen Therapeutics Reports Business and Financial Results for the First Quarter Ended March 31, 2016

May 04, 2016 - PR Newswire
Board and Executive Moves

 Orexigen Therapeutics, Inc. (Nasdaq: OREX) today announced business and financial results for the first quarter ended March 31, 2016.

"In preparation for the completion of our acquisition of U.S. rights to Contrave¬ģ (naltrexone HCl/bupropion HCl extended release), our team has made rapid progress advancing our commercial plans, including assembling talented and experienced sales and marketing leadership," said Mike Narachi, CEO of Orexigen.

Narachi continued: "We believe patients ...